CryoLife, Inc. is a distributor of cryogenically preserved human tissues for cardiac and vascular transplant applications and develops medical devices. Among its products are human heart valves, which are treated to remove excess cellular material and antigens, and BioGlue surgical adhesive.CryoLife, Inc. incorporated in 1984 in Florida, was the first biomedical company to specialize in the ultra-low temperature preservation of human heart valves used for cardiac reconstruction, primarily in children born with heart defects. The Company preserves and distributes human tissues and develops, manufactures, and commercializes medical devices for cardiac and vascular transplant applications. The human tissues distributed by CryoLife include the CryoValve® SG pulmonary human heart valve and the CryoPatch® SG pulmonary cardiac patch tissue, both processed using CryoLife’s proprietary SynerGraft® technology. CryoLife’s medical devices consist primarily of surgical adhesives, sealants, and hemostats including BioGlue® Surgical Adhesive, BioFoam® Surgical Matrix, PerClot®, which the Company began distributing for Starch Medical, Inc. in October 2010.The Company preserves small diameter human saphenous vein conduits for use in peripheral vascular reconstructions and coronary bypass surgery. Failure to achieve revascularization of an obstructed vessel may result in the loss of a limb or even death of the patient. When patients require bypass surgery, the surgeon’s first choicegenerally is the patient’s own vein tissue. However, in cases of advanced vascular disease, 30% of patients have unsuitable vein tissue for transplantation, and the surgeon must consider using synthetic grafts or preserved human vascular tissue. Small diameter synthetic vascular grafts are generally not optimal for below-the-knee surgeries because they have a tendency to obstruct over time. Preserved human vascular tissues tend to remain open longer and as such are used in indications where synthetics typically fail. In addition, synthetic grafts are not suitable for use in infected areas since they may harbor bacteria and are difficult to treat with antibiotics. Preserved human vascular tissues are ideal grafts for patients with previously infected graft sites. The Company also preserves femoral veins and arteries and aortoiliac arteries for bypass orreconstruction within infected surgical areas. Wikipedia.
CryoLife | Date: 2010-03-11
An antibiotic composition is provided for use in decontaminating biological tissue, for example, graft tissues for transplantation or preparation for terminal sterilization. The antibiotic composition is a physiological solution includes a lantibiotic, such as nisin. The antibiotic solution is effective to substantially inhibit bacterial growth of at least one type of gram-positive bacteria while substantially maintaining the physiological characteristics of the tissue. The method may include contacting the tissue with the antimicrobial composition at a temperature and for a period of time effective to substantially inhibit bacterial growth of the at least one type of gram-positive bacteria while substantially maintaining the physiological characteristics of the tissue.
CryoLife | Date: 2014-02-27
An apparatus and method are provided to treat a stenosis. A delivery device is provided that has an elongate tubular member coupled therewith. The elongate tubular member has an outside surface that is configured to prevent adherence of in vivo matter. The tubular member has a proximal end and a distal end and is reinforced along its length to maintain open lumen under a transverse load. The tubular member is placed in the vasculature such that the distal end of the elongate tubular member is disposed distal of a stenosis. The proximal end of the elongate tubular member is disposed inside the vessel, preferably at a location proximal of the stenosis. Thereafter, after a therapeutic period, the elongate tubular member is removed intact.
CryoLife | Date: 2015-02-18
Methods are provided that include applying to a surgical field in the patient following a lymphadenectomy or other procedure in which a lymph node or lymphatic vessel is dissected, a bioresorbable and biocompatible material in an amount effective to control oozing of lymphatic fluid. The material may be a hydrophilic polysaccharide material which, in contact with tissues in the surgical field, produces a gelled matrix that adheres to and forms a mechanical barrier with tissues in the surgical field to control oozing of lymphatic fluid. The hydrophilic polysaccharide material may include a modified starch such as a cross-linked carboxymethyl polysaccharide.
CryoLife | Date: 2010-07-06
A method is provided for preparing a tissue implant for implantation. The method includes harvesting a tissue material from a human or an animal donor, treating the tissue material with water or a hypotonic solution to lyse native cells of the tissue material, treating the tissue material in a nuclease-containing solution which includes an antimicrobial, treating the tissue material with an alkaline alcohol solution, treating the tissue material with a chlorine dioxide treatment solution, and sterilizing the tissue material.
CryoLife | Date: 2010-07-23
A method of preparing a tissue graft material is disclosed. The disclosure also relates to a multipurpose tissue graft material and to methods of using same as a replacement for vascular and non-vascular tissue.